VALN - Valneva adds 14% on European recommendation for COVID-19 shot

Valneva SE (NASDAQ:VALN) climbed ~14% in the morning hours Thursday after the French biotech announced that an expert panel of the European Medicines Agency (EMA) recommended the marketing authorization for its COVID-19 vaccine. EMA’s Committee for Medicinal Products for Human Use has endorsed the inactivated whole-virus COVID-19 vaccine candidate, VLA2001 for primary vaccination in those aged 18 to 50 years. The European Commission (EC) is expected to review the CHMP decision shortly for a final decision on marketing authorization. If cleared, VLA2001 will be the first COVID-19 shot to receive standard marketing authorization in Europe, the company said. “We are pleased that the CHMP has recommended VLA2001, the only inactivated COVID-19 vaccine candidate in Europe, for full marketing authorization and are now looking forward to receiving marketing authorization from the EC,” Valneva (VALN) Chief Executive Thomas Lingelbach added.

For further details see:

Valneva adds 14% on European recommendation for COVID-19 shot